https://doctransparency.com/doctor/tx/el-paso/sanjay-chabra-1316916125
Medicare Enrolled

Dr. Sanjay Chabra, D.O.

Rheumatology · El Paso, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
2600 N OREGON ST, El Paso, TX 79902
9153171660
In practice since 2006 (20 years)
NPI: 1316916125 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Chabra from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chabra? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Chabra

Dr. Sanjay Chabra is a rheumatology in El Paso, TX, with 20 years in practice. Based on federal Medicare data, Dr. Chabra performed 257,179 Medicare services across 1,591 unique beneficiaries.

Between the years covered by Open Payments, Dr. Chabra received a total of $3,318,791 from 51 pharmaceutical and/or device companies across 4845 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Chabra is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice▲ Top 3% volume in TX$ $3,318,791 industry payments

Medicare Practice Summary

Medicare Utilization ↗
257,179
Medicare services
Top 3% in TX for rheumatology
1,591
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~12,859 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Tocilizumab injection (Actemra)172,720$5$14
Certolizumab injection (Cimzia)52,400$4$13
Golimumab infusion (Simponi Aria)25,352$10$33
Denosumab injection (Prolia/Xgeva)2,880$18$54
Office visit, established patient (30-39 min)1,201$75$270
Administration of chemotherapy into vein, 1 hour or less792$98$345
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle358$54$189
Office visit, established patient, complex (40-54 min)356$117$364
Injection, ketorolac tromethamine, per 15 mg221$0$5
Injection of additional new drug or substance into vein177$12$85
Administration of chemotherapy into vein, each additional hour157$21$110
Drug injection, under skin or into muscle145$10$64
Injection, methylprednisolone sodium succinate, up to 125 mg108$4$22
New patient office visit (45-59 min)97$113$410
New patient office visit, complex (60-74 min)75$144$521
Office visit, established patient (20-29 min)55$37$184
Injection, methylprednisolone acetate, 80 mg34$8$40
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less21$48$270
Joint injection, major joint16$52$175
Injection, methylprednisolone sodium succinate, up to 40 mg14$3$10
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
9.9% high complexity
89.4% medium
0.7% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$3,318,791
Total received (2018-2024)
Avg $474,113/year across 7 years
Top 0% in TX for rheumatology
51
Companies
4,845
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$3,188,533 (96.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$124,678 (3.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,580 (0.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$497,213
2023
$484,331
2022
$573,333
2021
$432,442
2020
$298,980
2019
$586,206
2018
$446,285

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Horizon Therapeutics plc
$682,814
Amgen Inc.
$371,512
Lilly USA, LLC
$285,721
AbbVie Inc.
$221,052
ABBVIE INC.
$196,096
AstraZeneca Pharmaceuticals LP
$189,005
Horizon Pharma plc
$185,124
GlaxoSmithKline, LLC.
$180,125
Celgene Corporation
$159,736
UCB, Inc.
$147,373
GENZYME CORPORATION
$146,479
Aurinia Pharma U.S., Inc.
$121,206
AbbVie, Inc.
$116,856
Novartis Pharmaceuticals Corporation
$83,015
PFIZER INC.
$64,495
Mallinckrodt Hospital Products Inc.
$58,666
ANI Pharmaceuticals, Inc.
$30,612
Mallinckrodt Enterprises LLC
$23,960
Exeltis, USA Inc.
$13,366
Mallinckrodt LLC
$7,033
Janssen Biotech, Inc.
$6,998
Eli Lilly and Company
$6,400
Regeneron Healthcare Solutions, Inc.
$4,871
Genentech USA, Inc.
$4,713
Pfizer Inc.
$4,228
SOBI, INC
$1,854
NOVARTIS PHARMACEUTICALS CORPORATION
$1,725
SANOFI-AVENTIS U.S. LLC
$943
Actelion Pharmaceuticals US, Inc.
$388
Sobi, Inc
$314
Boehringer Ingelheim Pharmaceuticals, Inc.
$297
Genentech, Inc.
$280
Radius Health, Inc.
$224
Alexion Pharmaceuticals, Inc.
$175
Ultragenyx Pharmaceutical Inc.
$145
Flexion Therapeutics, Inc.
$136
Organon Llc
$134
E.R. Squibb & Sons, L.L.C.
$114
Takeda Pharmaceuticals U.S.A., Inc.
$95
DePuy Synthes Sales Inc.
$84
Janssen Pharmaceuticals, Inc
$76
Fresenius Kabi USA, LLC
$61
Gilead Sciences, Inc.
$61
MEDAC PHARMA, INC.
$45
Cardinal Health Inc
$43
Bioventus LLC
$39
Teva Pharmaceuticals USA, Inc.
$33
Biogen, Inc.
$28
Daiichi Sankyo Inc.
$17
Janssen Scientific Affairs, LLC
$14
Pacira Therapeutics, Inc.
$12
Top 3 companies account for 40.4% of total payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · Amitiza · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · Crysvita · DUEXIS · Dojolvi · EVENITY · Enbrel · Exogen · FORTEO · GELSYN 3 · Gazyva · HADLIMA · HUMIRA · Humira · IDACIO · ILARIS · INFLECTRA · INJECTAFER · KEVZARA · KEVZARA SARILUMAB INJECTION · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · MONOVISC · NO PRODUCT DISCUSSED · NO_PRODUCT · NUCALA · OFEV · OLUMIANT · OPSUMIT · ORENCIA · ORTHOVISC · Otezla · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · RHEUMATOID ARTHRITIS DISEASE · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · STELARA · SYNAGIS · Strensiq · TALTZ · TAVNEOS · TEPEZZA · TEZSPIRE · TREMFYA · Tavneos · Truxima · Tymlos · UPLIZNA · UPTRAVI · Uloric · Ultomiris · VIMOVO · VRAYLAR · XELJANZ · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (96%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for rheumatology in TX.

Equivalent to $1,290 per 100 Medicare services performed
Looking for a rheumatology in El Paso?
Compare rheumatologys in the El Paso area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
8
Per 100K population
0.9
County median income
$58,859
Nearest hospital
THE HOSPITALS OF PROVIDENCE - MEMORIAL CAMPUS
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Chabra is a mixed practice specialist, with above-average Medicare volume (top 3% in TX), and high industry engagement (speaking/promotional, top 0%), with 20 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Chabra experienced with tocilizumab injection (actemra)?
Based on Medicare claims data, Dr. Chabra performed 172,720 tocilizumab injection (actemra) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chabra receive payments from pharmaceutical companies?
Yes. Dr. Chabra received a total of $3,318,791 from 51 companies across 4,845 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chabra's costs compare to other rheumatologys in El Paso?
Dr. Chabra's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chabra) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →